| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Hapvida Participações e Investimentos S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$959.50 |
| 52 Week High | R$1,055.50 |
| 52 Week Low | R$867.50 |
| Beta | 0.67 |
| 11 Month Change | -4.72% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.10% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HAPV3 | AR Healthcare | AR Market | |
|---|---|---|---|
| 7D | 9.0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how HAPV3 performed against the AR Healthcare industry.
Return vs Market: Insufficient data to determine how HAPV3 performed against the AR Market.
Price Volatility
| HAPV3 volatility | |
|---|---|
| HAPV3 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: HAPV3 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HAPV3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | n/a | Jorge Fontoura Pinheiro de Lima | ri.hapvida.com.br |
Hapvida Participações e Investimentos S.A., together with its subsidiaries, operates in the health sector in Brazil. The company offers medical and dental insurance plans. It also provides medical and paramedical, laboratory, diagnostic, imaging, and ultrasound services, as well as organizes courses, lectures, seminars, and other events.
Hapvida Participações e Investimentos S.A. Fundamentals Summary
| HAPV3 fundamental statistics | |
|---|---|
| Market cap | AR$4.72t |
| Earnings (TTM) | -AR$51.91b |
| Revenue (TTM) | AR$4.57t |
1.1x
P/S Ratio-93.4x
P/E RatioIs HAPV3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAPV3 income statement (TTM) | |
|---|---|
| Revenue | R$27.65b |
| Cost of Revenue | R$20.18b |
| Gross Profit | R$7.46b |
| Other Expenses | R$7.78b |
| Earnings | -R$313.81m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 26.99% |
| Net Profit Margin | -1.14% |
| Debt/Equity Ratio | 22.4% |
How did HAPV3 perform over the long term?
See historical performance and comparison